On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

About a month after disclosing a $50 billion investment in its U.S. | Roche has earmarked more than $700 million to construct ...

Once again, AbbVie dominates doctors’ ranking of makers of immunology meds. | Just like last year, the Skyrizi and Rinvoq ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Medtronic has teamed up with Star Jones to get women talking about heart health. The TV personality is lending her star power ...

Get ready to rumble. In one corner, it’s President Donald Trump. In the other, it’s the pharmaceutical industry. | President ...

Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

The executive order adds on to Trump’s planned tariffs on pharmaceuticals in his overall strategy to onshore production of ...

Bristol Myers Squibb helmsman Chris Boerner joined a growing list of life sciences leaders announcing major U.S. investments ...